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Objective: To estimate the effect of increased body weight and body mass index (BMI) on pregnancy rates with levonorgestrel (LNG)
1.5 mg used as emergency contraception (EC).
Methods: The study reviewed data from 6873 women in four WHO-HRP randomized trials on EC conducted between 1993 and 2010.
Participants took either 1.5 mg of LNG as a single dose or in two doses 12 h apart, up to 120 h of unprotected intercourse. Contraceptive
efficacy (pregnancy rates) at different weight and BMI categories was evaluated.
Results: Overall pregnancy rate was low at 1.2%. Pregnancy rates were also low in women weighing over 80 kg (0.7%) and who were obese
(BMI over 30 kg/m2) (2.0%). The pooled analyses for pregnancy demonstrated that BMI over 30 kg/m2 decreased efficacy significantly
(odds ratio 8.27, 95% confidence interval = 2.70–25.37) when compared to women in lower BMI categories, mainly influenced by
pregnancies in obese women from one study site. Sensitivity analyses excluding that site showed that obesity was no longer a risk factor;
however, the other studies included too few obese women in the sample to exclude a substantial decrease in efficacy.
Conclusions: Pregnancy rates with use of LNG 1.5 mg for EC were low at less than 3% across different weight and BMI categories. Pooled
analyses showed an increase in pregnancy rates among obese women (BMI more than 30 kg/m2) compared to women with normal BMI
levels, influenced by pregnancies all coming from one study site.
Implications: Access to LNG as EC should still be promoted to women who need them, and not be restricted in any weight or BMI category,
with additional attention for counselling and advice for obese women.
© 2016 Published by Elsevier Inc.Keywords: Emergency contraception; Hormonal contraception; Levonorgestrel; Body weight; Body mass index (BMI)1. Introduction
Reasons for using emergency contraception (EC) include
possible contraceptive method failure or a possible incident
of unprotected sex. Among the factors that affect the risk of
pregnancy with use of levonorgestrel (LNG) as EC are the
timing of drug intake in relation to intercourse, additional
acts of intercourse after drug intake and the day of the cycle⁎ Corresponding author. Tel.: +41-227913267.
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0010-7824/© 2016 Published by Elsevier Inc.intercourse took place. LNG 1.5-mg pill is the most common
method of EC and can be usually taken up to 120 h after an
unprotected intercourse [1].
The finding that LNG as EC may be less effective in
women with increased body mass index (BMI) was
highlighted in the paper by Glasier et al. [2]. The analyses
of pooled data came from two studies — the first had 773
participants who took LNG as EC up to 72 h after
unprotected intercourse, and the second had 958 participants
who took it up to 120-h delay. The reported pregnancy rates
with LNG 1.5 mg were 2.5% [95% confidence interval (CI),
1.3%–4.6%] in overweight (BMI of 25–30 kg/m2) and
5.8% (95% CI, 3.5%–9.5%) in obese (BMI≥30 kg/m2)
women while it was only 1.3% (95% CI, 0.8%–2.2%) in
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covariates in the analyses that were significantly associated
with pregnancy risk included the probability of conception at
time of intercourse and having additional acts of intercourse after
EC intake. There were concerns whether these results on the use
of LNG as EC can be applied inwomen of higher weight outside
of the US and the UK where these studies were conducted.
Another report by Kapp et al. which analysed the same data
on the 1731 participants from these two studies showed that
LNG was less efficacious in preventing pregnancy in women
with higher body weight and higher BMI [3]. The estimated
pregnancy rate increased four- to fivefold in higher weight
categories or with increased BMI. This further supports the
need for the question on whether the regimen of LNG 1.5 mg
as ECwas useful in preventing pregnancy in the higher weight
and BMI categories and possibly in varied population settings.
From 1993 to 2010, the United Nations Development
Programme (UNDP)/United Nations Population Fund
(UNFPA)/United Nations Children's Fund (UNICEF)/
World Health Organization (WHO)/World Bank Special
Programme on Research and Research Training in Human
Reproduction (HRP) conducted four randomized clinical
trials involving the use of LNG 1.5 mg for EC [4–7]. In these
studies, treatment groups used LNG either as a single dose of
1.5 mg of LNG or as a double dose of 0.75 mg of LNG given
within a 12-h interval. Two of the trials were multicentre
studies in collaborating sites from Africa, Asia, Australia,
Europe and Latin America [5,6]. The other two trials were
single-country studies in Hong Kong and Nigeria [4,7].
Features of the studies are summarized in Table 1. Participants
were healthy women with regular menses, not using other
hormonal contraception and requesting EC within 120 h (as
defined in the respective trials) of an unprotected act of
intercourse. The main outcome was pregnancy. Piaggio et al.
previously published an analysis regarding the effect of delay
in administration of LNG for EC on pregnancy rates [8].
An analysis of a subset of these studies [5–7] by
Gemzell-Danielson et al. in 2015 reported 56 pregnancies
among 5812 women who received EC within 72 h following
unprotected intercourse and did not find any increased risk of
pregnancy with increasing bodyweight and BMI [9]. Limita-Table 1
Characteristics of WHO EC trials using LNG
Trial EC regimen used in tria
A. Hong Kong 1993 [4] A prospective randomized
comparison ofLNGwithYuzpe regimen;Delay 0–48 h
Two LNG 0.75-mg dose
B. WHO 1998 [5] RCT of LNG versus Yuzpe regimen;
Delay 0–72 h
Two LNG 0.75-mg dose
C. WHO 2002 [6] Low-dose mifepristone and two
regimens of LNG; Delay 0–120 h
One LNG 1.5 mg dose T
with 12-h interval
D. Nigeria 2010 [7] A randomized double-blind study to
compare two regimens of LNG; Delay 0–120 h
One LNG 1.5 mg dose T
with 12-h interval
Total pooled data One LNG 1.5 mg dose T
with 12-h intervaltions reported in the paper include the low number of women in
the higher weight and BMI group. Obesity was not among the
initial factors considered for recruitment in the initial studies.
This present paper provides an analysis of the data from
the four studies supported by WHO HRP, building upon the
earlier analyses [8]. Pooling data from these trials includes
more women from several countries across the globe for
analyses of the relationship between weight and BMI with
the efficacy of LNG 1.5 mg as EC.2. Methodology
This report combines data involving 6873 women with
available outcome details, who had received 1.5 mg of LNG
for EC up to 120 h after an act of unprotected intercourse. In
each of the four studies, participants were randomized to EC
regimens as described in Table 1.
For the pooled analyses, all available potential factors— (a)
treatment dose; (b) delay of treatment since unprotected
intercourse; (c) age; (d) weight; (e) BMI; (f) outcome of
previous pregnancies; (g) conception probability; (h) further
acts of intercourse; and (i) time of drug intake relative to the day
of ovulationwere fitted in the statisticalmodelling. Bodyweight
and height were measured in all studies using standard clinic
scales (H. v. Hertzen personal communication, November 07
2014, and O. A. Dada, personal communication, March 2
2015). We included both body weight and BMI in the logistic
regression models with pregnancy as the outcome.
These studies were conducted in different time periods
and settings. We evaluated “study” as a four-level random
effect, looking at howmuch variation in the treatment outcome
exists between the studies. This approach differs from the
Gemzell-Daniellson analyses which looked at the grouping of
participants from continents or geographic regions [9]. The
multilevel analysis technique implemented with the SAS®
Mixed and GlimMix procedures was applied and introduced
study in themultilevelmodel as a random effect parameter. The
calculated intraclass correlation coefficient (ICC) yielded a
very small value of 0.0041 which indicates that only 0.41% of
the variability in treatment outcome is accounted for by thel Participating centres in
countries
Number of LNGcases
included in this
analyses (sample size)
s with 12-h interval 1 centre in Hong Kong 410 (440)
s with 12-h interval 21 centres in 14 countries 974 (1001)
wo LNG 0.75-mg doses 15 centres in 10 countries 2695 (2756)
wo LNG 0.75-mg doses 7 centres in Nigeria 2794 (3022)
wo LNG 0.75-mg doses 31 centres in 17 countries 6873 (7219)
Table 2
Demographic characteristics of participants from the included individual studies
Study and sample size Hong Kong 1993
(n=410)
WHO 1998
(n=974)
WHO 2002
(n=2695)
Nigeria 2010
(n=2794)
Total pooled data
(n=6873)
1. Mean age (SD) 26.6 (6.1) 27.3 (7.0) 27.2 (7.1) 26.6 (5.9) 27.0 (6.6)
2. Mean weight in kg (SD) 51.9 (6.6) 58.4 (10.4) 56.2 (8.7) 63.2 (10.5) 59.1 (10.3)
3. Weight categories, n (%)
3a. Weight in kg b − 75 408 (99.8%) 901 (92.5%) 2609 (96.8%) 2384 (85.5%) 6302 (91.8%)
3b. Weight in kg 75–80 0 35 (3.6%) 35 (1.3%) 198 (7.1%) 268 (3.9%)
3c. Weight in kg 80 ++ 1 (0.2%) 38 (3.9%) 51 (1.9%) 207 (7.4%) 297 (4.3%)
4. Mean height in cm (SD) 158.4 (6.7) 162.9 (6.4) 163.0 (6.1) 162.1 (7.5) 162.4 (6.9)
5. BMI categories as kg/m2, n (%)
5a. BMI (b− 25) 378 (93.3%) 821 (84.3%) 2469 (91.6%) 1760 (63.1%) 5428 (79.1%)
5b. BMI [25–30) 20 (4.9%) 127 (13.0%) 194 (7.2%) 799 (28.6%) 1140 (16.6%)
5c. BMI [30 ++) 7 (1.7%) 26 (2.7%) 32 (1.2%) 230 (8.2%) 295 (4.3%)
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patient-level characteristics. We also analysed for study type
(single-country vs. multicentre), resulting in even lower ICC of
0.0004 that is only 0.04% of the variability in treatment
outcome. Study and study typewere not statistically significant
effects with p-values 0.151 and 0.286, respectively. When
pooled analyses showed significant findings affecting outcome
which was assessed to be mainly coming from one site, a
sensitivity analysis was done excluding data from that site.
The calculations and statistical modelling were performed
with the SAS® system v.9.3 using logistic regression analysis
with stepwise selection. All the explanatory variables
mentioned previously were included in the modelling, with
weight and BMI categorized into commonly used levels.3. Results
The analyses included 6873 women (of the 7164 reported
as being in the LNG arms in the four studies) who had
complete data regarding treatment details and the outcome
(which was a positive pregnancy test result about 1 week after
a missedmenstrual bleeding and confirmed with an ultrasound
examination). Table 2 describes the main demographic
characteristics of the women included, showing the variations
in the distribution of weight and BMI grouping across the
studies, ranging from 0.2% to 7.4% for women weighing overTable 3
Pregnancy rates in various categories of weight and BMI from the included indiv
Study and sample size Hong Kong 1993 (410) WHO 1998
Number of pregnancies 12 10
Pregnancy rate 2.9 (1.3–4.6) 1.0 (0.4–1.7
Pregnancies (N,%) by weight (kg) group
a. Weight b − 75 11/408 (2.7%) 10/901 (1.1
b. Weight [75–80) 0 0/35 (0.0%)
c. Weight [80 ++) 0/1 (0.0%) 0/38 (0.0%)
Pregnancies (N, %) by BMI (kg/m2) group
a. BMI (b− 25) 10/378 (2.6%) 10/821 (1.2
b. BMI [25–30) 0/20 (0.0%) 0/127 (0.0%
c. BMI [30 ++) 0/7 (0.0%) 0/26 (0.0%)80 kg, and from 1.2% to 8.2% for women with BMI over
30 kg/m2. Therewas only 1woman out of 410 in theHK study
over 75 kg, while in theNigeria study, 405 out of 2794women
weigh 75 kg or more. In the HK study, only 6.6% of
participants hadBMI above 25 kg/m2 (overweight and obese),
while in the Nigerian study, the percentage was 36.8%.
3.1. Assessment of pregnancy rates in major risk categories
Table 3 shows the treatment outcome by major risk factors
that are generally considered for the LNG EC efficacy
analysis. The overall pregnancy rate remains low in all the
studies, at 1.2% (0.9–1.5), with a range of 0.6 (in the Nigerian
study) to 2.9% (in the Hong Kong study, which also had the
least sample size). The rates remained low among women
weighing over 80 kg (0.7%; 0.1%–2.7%) and whowere obese
(2.0%; 0.8%–4.6%). The pregnancy rates among the different
BMI categories showed low rates withwideCIs with the upper
range from 13.3 to 43.9% because of the very few numbers in
these groups. The pregnancies in the higher BMI groups were
only found in the WHO 2002 study and the study in Nigeria.
3.2. Adjusted regression model
Table 4 shows the adjusted regression model showing that
BMI over 30 kg/m2 or obesity provides a significant effect on
efficacy (Odds Ratio [OR] = 8.27, 2.70–25.37). Weight
categories (as shown in Table 3) got removed from the model.idual studies
(974) WHO 2002 (2695) Nigeria 2010 (2794) Total pooled data (6873)
44 17 83
) 1.6 (1.2–2.1) 0.6 (0.3–0.9) 1.208 (0.95–1.47)
%) 44/2609 (1.7%) 14/2384 (0.6%) 79/6302 (1.3%)
0/35 (0.0%) 1/198 (0.5%) 1/268 (0.4%)
0/51 (0.0%) 2/207 (1.0%) 2/297 (0.7%)
%) 42/2469 (1.7%) 6/1760 (0.3%) 68/5428 (1.3%)
) 2/194 (1.0%) 5/799 (0.6%) 7/1140 (0.6%)
0/32 (0.0%) 6/230 (2.6%) 6/295 (2.0%)
Table 4
Analyses of combined of four WHO HRP studies looking at number of
pregnancies, pregnancy rates
Variable (all four
studies)
Number of
pregnancies
Number of
women
Pregnancy
Rate (%)
Odds ratio
(95%C.I.)
BMI (b 25) kg/m2 68 5428 1.25 1.00 (Ref)
[25–30) kg/m2 7 1140 0.61 0.96 (0.42–2.21)
[30 ++) kg/m2 6 295 2.03 8.27 (2.70–25.37)
able 5
isk of pregnancy among obese women in the four studies
tudy and pregnancy status of
bese participants
Day of drug intake relative to
day of ovulation
All
Before On the
day
After
n % n % n % n
HO 1998 (92908) Not pregnant 7 26.9 9 34.6 10 38.5 26
HO 2002 (97902) Not pregnant 11 34.4 1 3.1 20 62.5 32
ong Kong 1993 Not pregnant 3 42.9 4 57.1 7
igeria 2010
(A15062)
Not pregnant 56 25.1 33 14.8 134 60.1 223
Pregnant 6 100.0 6
otal
Not pregnant 77 26.8 43 14.9 168 58.3 288
Pregnant 0 0 0 0 6 100.0 6
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efficacy in themodelwere delay in drug intakemore than 48 h,
additional acts of intercourse after drug intake and taking the
drug at the time of or after ovulation. This finding of the effect
of obesity was mainly due to the pregnancies in women from
the study site in Nigeria. There were no other pregnancies in
this category from the other studies. Sensitivity analysis
performed on the pooled subset without the Nigerian study
data excluded high BMI as a risk factor; however, this would
now be based on a much smaller number of women in this
group (Table 4a).
Table 5 shows the obese women by pregnancy status and
day of treatment related to ovulation. All of the obese women
who became pregnant (all from Nigeria) took the emergency
contraceptive pill after the expected date of ovulation. This
supports the increased efficacy of the drug if taken shortly
before or at the expected date of ovulation, based on its
biological effect of preventing ovulation [10].4. Discussion
The four WHO HRP studies provided a large amount of
data on LNG as EC on about 7000 patients worldwide [4–7].
This provides an important opportunity to address the
question of whether and how much weight or BMI affect
pregnancy rates after EC use. High BMI was among the main
factors that affected efficacy of EC, based on the modelling
in this analysis.
The HRP studies were conducted in different times (from
1993 to 2010) and did vary by coverage (single country and
multicentre). We looked at the pooled data as a hierarchical or
multilevel data with four potentially different clusters. Having
hierarchical data means that the data can be grouped accordingTable 4a
Analyses of combined of three WHO HRP studies looking at number of
pregnancies, pregnancy rates (excluding data from Nigeria)
Variables (excluding
data
from Nigeria)
Number of
pregnancies
Number of
women
Pregnancy
rate (%)
Odds ratio
(95% CI)
BMI (b25) kg/m2 62 3668 1.69
[25–30) kg/m2 2 341 0.59 Eliminated
[30 ++) kg/m2 0 65 0.00
Note.
Other factors that were shown to significantly affect pregnancy rates include
delay in treatment more than 48 h, further acts of pregnancy and timing of
drug intake in relation to time of ovulation (at day 0 and later).T
R
S
o
W
W
H
N
Tto factors (time periodwhen the studies were conducted, or type
of study— single vs. multicountry, etc.) that usually introduce
“intra-cluster homogeneity” and “between-cluster heterogene-
ity.” It can be assumed that within each study, data were
homogeneous as much as defined by a study protocol. Our
analyses did not find “study” and “study type” as significant
factors, implying that perceived variations in the study
characteristics may not have contributed to the outcome.
There were some unique features in the original reports of
the individual studies. These four studieswere already analysed
together to see the effect of treatment delay on the pregnancy
rates [8]. The issue of obesity was not taken into consideration
in this analysis. The proportion of obese women in the Nigeria
study is 8.2% (229/2794), while in the other three studies it is
only 1.6% (65/4079). Thus having the data from the Nigeria
study increases the proportion of obese women in the pooled
dataset to 4.3% (294/6873) for evaluation. This provided an
important opportunity to address the question of whether and
how much weight or BMI affect pregnancy rates after EC use.
Other features of the Nigeria study included lower reported
rates of using EC because of possible condom failure
(19.8–20.3% vs. 44–46%) and a higher likelihood of
participants being lost to follow-up compared to the women
in the 2002 WHO study (6.6% vs. 1.5%) [6,7]. This was also
considered in the analyses by Gemzell Danielsson, noting the
unique features of these women from this subset.
The initial pooled analysis shows that women of the BMI
obese category are at much higher risk (effect size more than 8)
of pregnancy compared to the normal weight women. These
results were consistent with the previously cited reports [2,3]
expressing the higher risk. The analyses by Gemzell Danielsson
who reported ORs relative to the BMI and weight categories,
with a single significant effect OR = 2.18 (95%CI, 1.03 to 4.62)
appearing at BMI 44 kg/m2 and body weight 80 kg [8].
Based on the pooled analyses, we noted that our findings
were mainly due to pregnancies reported in the obese women
from the Nigeria study site. This may have implications on
generalizability of results to other populations and to subgroups
of populations. The sensitivity analyses of the pooled data,
excluding the Nigeria data failed to show that BMI affected
efficacy; however, there were few obese women in the other
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the pregnancy rate (Table 4a).
As far as weight and BMI are concerned, across the defined
weight and BMI categories, the rates of pregnancies remain low
and were below 3.0%. The limitation of this pooled analysis is
that all four studies were not originally intended to be stratified
in the randomization according to weight or BMI of patients.5. Summary and conclusions
LNG 1.5 mg for EC results in pregnancy rates less than 3%
across different body weight and BMI categories. There was
an observed decrease in effect among obese women compared
to womenwith normal BMI levels. This was highly influenced
by treatment results in women from one subset of the study
population. The pregnancy rates in the various categories for
users of LNG as EC are still low, and provision of LNG should
not be restricted in any weight or BMI category based on these
data. While there may be other options for EC, LNG remains
the most widely available drug for EC.
The latest recommendations in the Medical Eligibility
Criteria for contraceptive use (fifth edition) do state that
women who are obese can use LNG as Emergency contracep-
tive pills without restriction (Medical Eligibility Criteria for
Contraceptive Use Category 1). ECPs may be less effective
among women with BMI≥30 kg/m2 than among women with
BMIb25 kg/m2. Despite this, there are no safety concerns [11].
Apart from weight and BMI, there are other factors to consider
when taking EC, such as timing of when to take LNG 1.5 mg as
EC, in relation to the sexual act, and to the day of ovulation.
Counselling and information on proper use should be provided.
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